Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 417 of 1,261
  1. US 10683277

    Triazole derivatives as P2Y14 receptor antagonists

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted
  2. US 10682425

    Engineered B lymphocytes and compositions having micro-RNA and methods for making and using them

    The Regents of the University of California · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted
  3. US 10682416

    Epicardial-derived paracrine factors for repairing cardiac tissue

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted
  4. US 10682379

    Use of gram negative species to treat atopic dermatitis

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted
  5. US 10682393

    Glial cell line derived neurotrophic factor, obesity, and obesity-related diseases and conditions

    United States Department of Veteran Affairs · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted
  6. US 10682388

    Targeting of PELP1 in cancer therapy

    The Board of Regents of the University of Texas System · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted
  7. US 10682339

    Pharmaceutical compositions directly targeting FKBP52 for the treatment of prostate cancer and methods of using same

    The Board of Regents of the University of Texas System · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted
  8. US 10683362

    Recombinant immunotoxin targeting mesothelin

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted
  9. US 10683270

    Cannabinoid receptor mediating compounds

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted
  10. US 10682310

    Therapeutic compounds and formulations for intranasal delivery

    Regents of the University of Minnesota · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted
  11. US 10683279

    Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

    Enanta Pharmaceuticals, Inc. · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted
  12. US 10683272

    Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy

    Northwestern University · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted
  13. US 10682350

    2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted
  14. US 10682418

    Polymer-sunitinib conjugates

    Nektar Therapeutics · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted
  15. US 10683347

    Treatment of cancer using anti-TGF-β and anti-PD-1 antibodies

    The Regents of the University of California · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted
  16. US 10683363

    Targeting intracellular target-binding determinants with intracellular antibodies

    The United States of America as represented by the Department of Veteran Affairs · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted
  17. AU 2018379646

    Dopamine-B-hydroxylase inhibitors

    BIAL PORTELA & Cª S A [PT] · Granted Jun 11, 2020 · Expires Jun 6, 2040

    granted
  18. US 10675272

    Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease

    PTC THERAPEUTICS, INC. · Granted Jun 9, 2020 · Expires Jun 4, 2040

    granted
  19. US 10676530

    Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an antibody to IL-4 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 9, 2020 · Expires Jun 4, 2040

    granted
  20. US 10675358

    Antibody adjuvant conjugates

    Bolt Biotherapeutics, Inc. · Granted Jun 9, 2020 · Expires Jun 4, 2040

    granted
  21. US 10675258

    Method of using gamma-hydroxybutyrate compositions for the treatment of disorders

    Jazz Pharmaceuticals Ireland Limited · Granted Jun 9, 2020 · Expires Jun 4, 2040

    granted
  22. US 10675304

    Combination immunotherapies for treatment of cancer

    PrimeVax Immuno-Oncology · Granted Jun 9, 2020 · Expires Jun 4, 2040

    granted
  23. US 10676474

    1,6-naphthyridine derivatives as CDK4/6 inhibitor

    Medshine Discovery Inc. · Granted Jun 9, 2020 · Expires Jun 4, 2040

    granted
  24. US 10675341

    Parenteral norovirus vaccine formulations

    Takeda Vaccines, Inc. · Granted Jun 9, 2020 · Expires Jun 4, 2040

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.